7. SEGMENTS

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

6. SEGMENTS

The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  The Company also operates an FDA-licensed source plasma collection facility located in Norcross, Georgia.  The Company defines its segments as those business units for which operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources.

The plasma collection center segment includes the Company’s operation in Georgia.  The research and development segment includes the Company’s plasma development operations in New Jersey.

Summarized financial information concerning reportable segments is shown in the following table:

	Plasma
Three Months Ended	Collection			Research and
September 30, 2013	Center			Development			Corporate			Consolidated
Revenues	$	1,088,452		$	-		$	18,889		$	1,107,341
Cost of product revenue		726,245			-			-			726,245
Gross profit		362,207			-			18,889			381,096
Loss from operations		(295,569	)		(1,408,990	)		(826,412	)		(2,530,971	)
Other expense		(1,863	)		-			(156,113	)		(157,976	)
Loss before income taxes		(297,432	)		(1,408,990	)		(982,525	)		(2,688,947	)
Property and equipment, net		624,492			3,539			183,367			811,398
Depreciation and amortization expense		43,043			809			11,035			54,887

	Plasma
Three Months Ended	Collection			Research and
September 30, 2012	Center			Development			Corporate			Consolidated
Revenues	$	360,338		$	-		$	-		$	360,338
Cost of product revenue		144,691			-			-			144,691
Gross profit		215,647			-			-			215,647
Loss from operations		(273,653	)		(1,940,637	)		(1,034,530	)		(3,248,820	)
Other income (expense)		(2,095	)		-			5,168			3,073
Loss before income taxes		(275,748	)		(1,940,637	)		(1,029,362	)		(3,245,747	)
Property and equipment, net		701,637			16,306			85,766			803,709
Depreciation and amortization expense		40,517			4,206			4,173			48,896

	Plasma
Nine Months Ended	Collection			Research and
September 30, 2013	Center			Development			Corporate			Consolidated
Revenues	$	2,618,361		$	-		$	25,185		$	2,643,546
Cost of product revenue		1,741,052			-			-			1,741,052
Gross profit		877,309			-			25,185			902,494
Loss from operations		(835,749	)		(6,346,924	)		(3,341,514	)		(10,524,187	)
Other expense		(5,784	)		-			(296,067	)		(301,851	)
Loss before income taxes		(841,533	)		(6,346,924	)		(3,637,581	)		(10,826,038	)
Property and equipment, net		624,492			3,539			183,367			811,398
Depreciation and amortization expense		129,325			2,428			27,322			159,075

	Plasma
Nine Months Ended	Collection			Research and
September 30, 2012	Center			Development			Corporate			Consolidated
Revenues	$	594,834		$	-		$	-		$	594,834
Cost of product revenue		288,761			-			-			288,761
Gross profit		306,073			-			-			306,073
Loss from operations		(1,021,688	)		(2,201,131	)		(2,446,043	)		(5,668,862	)
Other income (expense)		(6,465	)		-			7,936			1,471
Loss before income taxes		(1,028,153	)		(2,201,131	)		(2,438,107	)		(5,667,391	)
Property and equipment, net		701,637			16,306			85,766			803,709
Depreciation and amortization expense		121,553			12,618			6,572			140,743

The “Corporate” column includes general and administrative overhead expenses.  Property and equipment, net, included in the “Corporate” column above includes assets related to corporate and support functions.